A Study of Dalotuzumab + MK-2206 and Dalotuzumab + MK-0752 Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Official Title

Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206 and MK-0646 (Dalotuzumab) + MK-0752 Doublets (MK-MK Doublets) in Patients With Advanced Cancer


This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206 or dalotuzumab + MK-0752. Preliminary anti-tumor activity of these combinations in groups of participants with specific types of cancer will be assessed. The study will determine the dose limiting toxicities (DLTs) observed after administration of each of the combinations at various doses and define the maximum tolerated dose of each combination.

Trial Description

Primary Outcome:

  • Number of participants with dose limiting toxicities (DLTs)
  • Number of participants whose best response is a partial response (PR) or complete response (CR)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society